Neurobiological Technologies Stock Net Income
Neurobiological Technologies fundamentals help investors to digest information that contributes to Neurobiological Technologies' financial success or failures. It also enables traders to predict the movement of Neurobiological Stock. The fundamental analysis module provides a way to measure Neurobiological Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobiological Technologies stock.
Neurobiological |
Neurobiological Technologies Company Net Income Analysis
Neurobiological Technologies' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Neurobiological Technologies Net Income | 4.94 M |
Most of Neurobiological Technologies' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Neurobiological Technologies reported net income of 4.94 M. This is 98.55% lower than that of the Biotechnology sector and 92.94% lower than that of the Health Care industry. The net income for all United States stocks is 99.13% higher than that of the company.
Neurobiological Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobiological Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobiological Technologies could also be used in its relative valuation, which is a method of valuing Neurobiological Technologies by comparing valuation metrics of similar companies.Neurobiological Technologies is currently under evaluation in net income category among its peers.
Neurobiological Fundamentals
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Shares Owned By Institutions | 9.41 % | ||||
| Number Of Shares Shorted | 37.6 K | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 26.35 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Short Ratio | 0.09 X | ||||
| Target Price | 6.0 | ||||
| Beta | -408.27 | ||||
| Market Capitalization | 10.86 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
| Z Score | 27.29 | ||||
| Net Asset | 2.58 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |